Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,035 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Soft Tissue Neoplasms Clear all

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Interventions: Oral repotrectinib (TPX-0005); Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: Up to 25 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more

Conditions: Soft Tissue Sarcoma
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Menlo Park, California • San Francisco, California • San Rafael, California + 15 more

Conditions: Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Tumors (With PI Approval), Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 6 Months to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: becatecarin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 198
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma, Osteosarcoma, Ewing Sarcoma of Bone
Interventions: Gemcitabine, 9-ING-41, Docetaxel; Drug
Lead sponsor: Brown University; Other
Eligibility: 10 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
Interventions: Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration; Drug · Biological · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 194
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more

Conditions: Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
Interventions: Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin

Conditions: Rhabdomyosarcoma
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
Interventions: Dexrazoxane, Doxorubicin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leiomyoma
Interventions: ExAblate 2000; Device
Lead sponsor: InSightec; Industry
Eligibility: Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
Interventions: PRT1419; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more

Conditions: Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions: Ascorbate, Gemcitabine; Drug
Lead sponsor: Mohammed Milhem, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Ewing's Sarcoma
Interventions: Vigil, Temozolomide, Irinotecan, Gemcitabine, Docetaxel; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more

Conditions: Metastatic Osteosarcoma
Interventions: doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis; Drug · Biological · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Sarcoma, Bone, Sarcoma, Soft Tissue, Osteosarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft-tissue Sarcoma
Interventions: Diffusion Weighted Magnetic Resonance Imaging; Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions: TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Aurora, Colorado • Iowa City, Iowa + 6 more

Conditions: Lymphoma, Sarcoma
Interventions: Electrocardiogram, Echocardiogram, LVEF echocardiogram, Apple Watch, Biospecimen collection, Questionnaires, Cardio-pulmonary exercise test, 6 minute walk test, Grip strength test; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Symptomatic Uterine Fibroids and Adenomyosis
Interventions: IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Interventions: Simvastatin 40mg, Placebo 40 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Soft Tissue Sarcoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tecogalan sodium; Drug
Lead sponsor: Daiichi Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall

A Study of Patients With AIDS Syndrome

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids

A Study of PRT1419 in Patients With Advanced Solid Tumors

Gemcitabine Plus Ascorbate for Sarcoma in Adults

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

Effects of Simvastatin on Uterine Leiomyoma Size

Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study

A Study of Tecogalan Sodium